Detalles de la búsqueda
1.
Single-dose administration of MK-0657, an NR2B-selective NMDA antagonist, does not result in clinically meaningful improvement in motor function in patients with moderate Parkinson's disease.
J Clin Pharmacol;
49(7): 856-64, 2009 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-19491335
2.
Methodological Extensions of Phase 2 Trial Designs Based on Program-Level Considerations: Further Development of a Case Study in Neuropathic Pain.
Ther Innov Regul Sci;
51(1): 100-110, 2017 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-30236005
Resultados
1 -
2
de 2
1
Próxima >
>>